Studying spinal fluid and blood tests in lung cancer spreading to the brain lining
Compares tumor DNA in spinal fluid and blood in adults with EGFR lung cancer.
Plain-language title generated from the registry record
Registry title: CSF Analysis in EGFR Mutant Non-Small Cell Lung Cancer With Leptomeningeal Disease
Key facts
- Where
- Vancouver, CanadaSee the site
Where in Canada
- BC CancerVancouver, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- British Columbia Cancer Agency
- Trial code
- NCT05257967
- Record updated
- 19 October 2026
- Original description
Leptomeningeal disease is malignant seeding of the leptomeninges and presents with a variety of symptoms frequently impacting quality of life. With improvement in treatment options, rates of leptomeningeal disease are increasing and currently found in up to 9% of EGFR mutant NSCLC.Read full original descriptionShow less
CSF Liquid Biopsy Based Characterization of Leptomeningeal Disease in EGFR Mutant Non-Small Cell Lung Cancer
Leptomeningeal disease is malignant seeding of the leptomeninges and presents with a variety of symptoms frequently impacting quality of life. With improvement in treatment options, rates of leptomeningeal disease are increasing and currently found in up to 9% of EGFR mutant NSCLC.
Systemic therapy may be more effective if it can target the correct molecular aberration. The molecular characterization of central nervous system disease may differ from disease outside of the central nervous system. The aim of this pilot trial is to evaluate for molecular differences between cerebral spinal fluid (CSF) and blood circulating tumor DNA (ctDNA) through the use of ddPCR and BC Cancer NGS panel molecular testing.
Inclusion: Subject age is greater than or equal to 18 years at the time of signature of informed consent; Histologically or cytologically confirmed metastatic EGFR mutant NSCLC; Leptomeningeal disease based on brain MRI or CSF cytology; ECOG 0-3; Life expectancy of at least 8 weeks; Adequate hematologic and end organ function for testing; Ability to give informed consent for the study procedures defined in this protocol.
Exclusion: Inability to undergo a lumbar puncture due to thrombocytopenia, bleeding disorders, as well as inability to cooperate or consent to procedure; MRI spine demonstrating spinal leptomeningeal disease preventing a safe lumbar puncture; Subjects who are otherwise felt by the treating clinician to be unfit to proceed with this protocol.